Detection of metastases in lymph nodes using quantitative ultrasound

Information

  • Research Project
  • 9326825
  • ApplicationId
    9326825
  • Core Project Number
    R01CA192407
  • Full Project Number
    5R01CA192407-03
  • Serial Number
    192407
  • FOA Number
    PAR-13-169
  • Sub Project Id
  • Project Start Date
    8/1/2015 - 10 years ago
  • Project End Date
    7/31/2020 - 5 years ago
  • Program Officer Name
    BAKER, HOUSTON
  • Budget Start Date
    8/1/2017 - 8 years ago
  • Budget End Date
    7/31/2018 - 7 years ago
  • Fiscal Year
    2017
  • Support Year
    03
  • Suffix
  • Award Notice Date
    7/18/2017 - 8 years ago

Detection of metastases in lymph nodes using quantitative ultrasound

? DESCRIPTION (provided by applicant): This application proposes an Academic-Industrial Partnership (AIP) consisting of Riverside Research (RR) in New York, NY, as the primary partner in collaboration with the GE Global Research Center (GE) in Niskayuna, NY, as the industrial partner, and with the Stony Brook Medical (SBM) affiliated with the State University of New York in Stony Brook, NY, and the Kuakini Medical Center (KMC) affiliated with the University of Hawaii in Honolulu, HI, as the clinical/academic partners. The proposed project addresses the need for reliable, highly sensitive means of detecting metastases to lymph nodes (LNs) in order to correctly stage and optimally treat cancer. Accordingly, we seek to validate existing encouraging results obtained by RR and KMC using quantitative-ultrasound (QUS) methods for detecting metastases in LNs by applying and evaluating these promising methods using a far larger number of LNs and including a far broader range of cancer types from a more-diverse patient population than has been possible in studies to date. Validation efforts will include development, deployment and evaluation of a pre-prototype ultrasonic instrument for QUS-based detection and imaging of metastases in the pathology laboratory. Successful validation will establish a foundation for translation of the QUS methods into a compact, low-cost instrument for metastases detection in dissected LNs to be used in the pathology laboratory or possibly in the operating room. Successful validation also will establish the foundation for a subsequent instrument that can detect and image nodal metastases intra-operatively in the operating room or pre-operatively in the examination room. The AIP partners will synergize capabilities in the following general ways: RR will provide project oversight and coordination and will apply, refine, and test the QUS methods; GE will provide ultrasound (US) instrumentation by designing, fabricating, and characterizing a pre-prototype device; SBM and KMC will provide clinical support by recruiting patients and acquiring US and histological data from dissected LNs.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R01
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
    573544
  • Indirect Cost Amount
    107232
  • Total Cost
    680776
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:680776\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    RIVERSIDE RESEARCH INSTITUTE
  • Organization Department
  • Organization DUNS
    046822615
  • Organization City
    NEW YORK
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    100382609
  • Organization District
    UNITED STATES